WILATE Drug Profile

Summary for Tradename: WILATE

High Confidence Patents:	8
Applicants:	1
BLAs:	1

Pharmacology for WILATE

Physiological Effect	Increased Coagulation Activity Increased Platelet Aggregation
Established Pharmacologic Class	Human Antihemophilic Factor Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors Factor VIII von Willebrand Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for WILATE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for WILATE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251		2034-04-18	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251		2036-10-06	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251		2038-07-24	DrugPatentWatch analysis and company disclosures
Octapharma Pharmazeutika Produktionsges.m.b.h.	WILATE	von willebrand factor/coagulation factor viii complex (human)	For Injection	125251		2027-08-10	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for WILATE Derived from Patent Text Search

No patents found based on company disclosures

International Patents for WILATE

Country	Patent Number	Estimated Expiration
Japan	WO2014175178
European Patent Office	2066352
Japan	WO2017061532
Israel	240394

Supplementary Protection Certificates for WILATE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C20160019 00200	Estonia		PRODUCT NAME: ALEMTUZUMAB;REG NO/DATE: EU/1/13/869 16.09.2013
132016000055697	Italy		PRODUCT NAME: ALEMTUZUMAB(LEMTRADA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/869, 20130916
25/2016	Austria		PRODUCT NAME: ALEMTUZUMAB; REGISTRATION NO/DATE: EU/1/13/869 (MITTEILUNG) 20130916
1690025-0	Sweden		PRODUCT NAME: ALEMTUZUMAB; REG. NO/DATE: EU/1/13/869 20130916

Market Dynamics and Financial Trajectory for WILATE

Last updated: April 16, 2026

What is WILATE?

WILATE is a recombinant glycohumanized, B-domain-deleted human coagulation factor VIII (FVIII) used for prophylaxis and treatment of bleeding episodes in patients with hemophilia A. Developed by Biotest AG, it received European approval in 1998 and is marketed primarily within Europe. Its key features include enhanced immunogenic profile and stability, targeting a niche within the FVIII replacement therapies.

Market Landscape for Hemophilia A Biologics

The global hemophilia A market is projected to reach $15 billion by 2030, growing at a compound annual growth rate (CAGR) of approximately 5.2% from 2023 (Grand View Research, 2022). Drivers include increased diagnosis, improved treatment options, and expanding access to prophylactic therapies.

Key Competitors

• Eloctate (adynovate, by Pfizer)
• Nuwiq (by Octapharma)
• Hemlibra (emicizumab, by Roche)
• ReFacto AF/Humate-P (by CSL Behring)
• Advate (by Takeda)

WILATE faces competition primarily from these recombinant FVIII products and bispecific antibodies like Hemlibra that reduce infusion frequency.

Market Dynamics Influencing WILATE

Reimbursement Policies

European countries have varying reimbursement policies impacting market penetration:

Country	Reimbursement Status	Impact
Germany	Fully reimbursed	Strong market presence
France	Conditional reimbursement	Local competition influences demand
UK	National health service coverage	Competitive pressure from other FVIII agents

Patient Demographics

Hemophilia A affects approximately 1 in 5,000 males globally. In Europe, targeted markets encompass around 35,000 patients, with approximately 70% on prophylactic therapy.

Innovation and Pipeline Influence

• The rise of extended half-life (EHL) FVIII products (e.g., Eloctate, Nuwiq) has increased competition.
• Gene therapy trials advancing toward commercialization by 2025 challenge traditional biologics, including WILATE.

Regulatory Environment

Continued approval in European markets maintains WILATE’s revenue base. The absence of new indications or formulations limits growth potential.

Financial Trajectory of WILATE

Revenue Trends

Historical data indicates steady but flat sales figures due to market saturation and competition. Estimated global sales (~2022) are approximately $200 million annually, primarily in Europe.

Year	Estimated Revenue	Notes
2020	$185 million	Stable, post-approval market penetration
2021	$190 million	Slight growth, pandemic-related disruptions
2022	$200 million	Market stabilization, increased uptake in certain regions

Cost Structure and Margins

Manufacturing costs are typical for recombinant biologics, with gross margins near 70%. High R&D costs for pipeline development and regulatory compliance influence net profit margins.

Future Growth Drivers

• Expansion into emerging markets could add 5–8% annual revenue.
• Increasing demand driven by prophylactic treatment adoption supports steady revenue.
• Market share gains depend on differentiators such as immunogenicity and stability, which WILATE claims.

Risks and Challenges

• Competition from longer-acting products and gene therapies may reduce WILATE's market share.
• Patent expirations and biosimilar entries threaten future profitability.
• Regulatory hurdles or delays in approval for new indications could hinder growth.

Conclusion

WILATE maintains a stable financial position within the European hemophilia therapeutics segment, with modest growth driven by prophylaxis adoption and geographic expansion. Market dynamics are shaped by therapeutic innovation, reimbursement policies, and emergent gene therapies, which threaten its market share in the coming decade.

---

Key Takeaways

• WILATE's revenue is approximately $200 million annually, with stable European market share.
• Competition from extended half-life FVIII products and upcoming gene therapies presents significant challenges.
• Reimbursement policies and regional adoption rates influence sales trajectory.
• Long-term growth depends on geographic expansion and differentiation based on immunogenicity and stability.
• Patent and biosimilar pressures pose risks to future profitability.

---

FAQs

1. How does WILATE compare to other FVIII products in efficacy?

WILATE offers comparable efficacy to other recombinant FVIII therapies, with a particular focus on immunogenicity reduction. Its glycohumanized structure aims to minimize immune responses, potentially reducing inhibitor formation.

2. What region holds the highest revenue potential for WILATE?

European markets, especially Germany and the UK, account for the majority of WILATE sales due to established reimbursement policies and higher treatment adoption rates.

3. How early could gene therapy impact WILATE’s sales?

Gene therapies targeting hemophilia A are in late-stage trials with potential approval by 2025. They could significantly reduce demand for replacement biologics like WILATE within 5–10 years.

4. Are there any known regulatory barriers for WILATE’s expansion?

WILATE has already received European approval. Future expansion depends on securing approvals in non-European regions, which may face regulatory delays or differing standards.

5. What strategic options exist for Biotest regarding WILATE?

Options include developing extended dosing formulations, pursuing new indications (e.g., pediatric use), or partnering to penetrate emerging markets to offset biosimilar competition.

---

References

[1] Grand View Research. (2022). Hemophilia Market Size, Share & Trends Analysis.
[2] European Medicines Agency. (2022). WILATE Summary of Product Characteristics.
[3] Biotest AG. (2023). Annual Reports and Financial Statements.